ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The U.S. biotech firm Amgen plans to increase its presence in Japan through an alliance with Japan’s Astellas Pharma. The new partners plan to cooperatively develop and commercialize in Japan five products—four biologics and one small molecule—from Amgen’s new-drug pipeline. The first commercial launch is expected by 2016. The partners also plan a Tokyo-based joint-venture company that will give Amgen on-the-ground capabilities in Japan starting this fall.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter